A citation-based method for searching scientific literature

Lois M Mulligan. Nat Rev Cancer 2014
Times Cited: 293



Elena Arighi, Maria Grazia Borrello, Hannu Sariola. Cytokine Growth Factor Rev 2005
Times Cited: 306




List of shared articles



Times cited

Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose.
Lingtian Zhang, Marialuisa Moccia, David C Briggs, Jaideep B Bharate, Naga Rajiv Lakkaniga, Phillip Knowles, Wei Yan, Phuc Tran, Anupreet Kharbanda, Xiuqi Wang,[...]. J Med Chem 2022
0

Resistance to RET targeted therapy in Thyroid Cancer: Molecular basis and overcoming strategies.
María San Román-Gil, Javier Pozas, Diana Rosero-Rodríguez, Jesús Chamorro-Pérez, Álvaro Ruiz-Granados, Ignacio Ruz Caracuel, Enrique Grande, Javier Molina-Cerrillo, Teresa Alonso-Gordoa. Cancer Treat Rev 2022
0


ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research.
C Belli, F Penault-Llorca, M Ladanyi, N Normanno, J-Y Scoazec, L Lacroix, J S Reis-Filho, V Subbiah, J F Gainor, V Endris,[...]. Ann Oncol 2021
28

Discovery and optimization of selective RET inhibitors via scaffold hopping.
Zhibo Luo, Lingli Wang, Zhifei Fu, Bin Shuai, Miaorong Luo, Guoping Hu, Jian Chen, Jikui Sun, Jiansong Wang, Jian Li,[...]. Bioorg Med Chem Lett 2021
0

Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development.
Debasmita Saha, Katie Rose Ryan, Naga Rajiv Lakkaniga, Baku Acharya, Noemi Garcia Garcia, Erica Lane Smith, Brendan Frett. J Med Chem 2021
1

Neuro-mesenchymal units control ILC2 and obesity via a brain-adipose circuit.
Filipa Cardoso, Roel G J Klein Wolterink, Cristina Godinho-Silva, Rita G Domingues, Hélder Ribeiro, Joaquim Alves da Silva, Inês Mahú, Ana I Domingos, Henrique Veiga-Fernandes. Nature 2021
20

Hallmarks of RET and Co-occuring Genomic Alterations in RET-aberrant Cancers.
Jacob J Adashek, Aakash P Desai, Alexander Y Andreev-Drakhlin, Jason Roszik, Gilbert J Cote, Vivek Subbiah. Mol Cancer Ther 2021
2

The Novel RET Inhibitor SYHA1815 Inhibits RET-Driven Cancers and Overcomes Gatekeeper Mutations by Inducing G1 Cell-Cycle Arrest through c-Myc Downregulation.
Yuchen Jiang, Xia Peng, Yinchun Ji, Yang Dai, Yanfen Fang, Bing Xiong, Wenming Ren, Youhong Hu, Yi Chen, Jing Ai. Mol Cancer Ther 2021
0

[Advances in the Treatment of RET Fusion-positive Advanced Non-small Cell Lung Cancer].
Qingyun Gao, Junwei Su, Faman Xiao, Xiaocheng Lin, Jinji Yang. Zhongguo Fei Ai Za Zhi 2021
0

PTPRA Phosphatase Regulates GDNF-Dependent RET Signaling and Inhibits the RET Mutant MEN2A Oncogenic Potential.
Leena Yadav, Elina Pietilä, Tiina Öhman, Xiaonan Liu, Arun K Mahato, Yulia Sidorova, Kaisa Lehti, Mart Saarma, Markku Varjosalo. iScience 2020
7

Advances in Targeting RET-Dependent Cancers.
Vivek Subbiah, Gilbert J Cote. Cancer Discov 2020
44

Targeting RET Kinase in Neuroendocrine Prostate Cancer.
Halena R VanDeusen, Johnny R Ramroop, Katherine L Morel, Song Yi Bae, Anjali V Sheahan, Zoi Sychev, Nathan A Lau, Larry C Cheng, Victor M Tan, Zhen Li,[...]. Mol Cancer Res 2020
13

Progresses Toward Precision Medicine in RET-altered Solid Tumors.
Carmen Belli, Santosh Anand, Justin F Gainor, Frederique Penault-Llorca, Vivek Subbiah, Alexander Drilon, Fabrice Andrè, Giuseppe Curigliano. Clin Cancer Res 2020
12

Discovery of 4-methyl-N-(4-((4-methylpiperazin- 1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-oxy)benzamide as a potent inhibitor of RET and its gatekeeper mutant.
Xiaoyang Li, Jingyi Su, Yanru Yang, Wenhua Lian, Zhou Deng, Zaiyou Yang, Guyue Chen, Baoding Zhang, Chao Dong, Xueyan Liu,[...]. Eur J Med Chem 2020
2

Targeted therapies for RET-fusion cancer: Dilemmas and breakthrough.
SiJie Ding, Rong Wang, ShunLi Peng, Xiaoqing Luo, LongHui Zhong, Hong Yang, YueYun Ma, ShiYu Chen, Wei Wang. Biomed Pharmacother 2020
1